Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
6.45
Nov 20 • 3:59 PM ET Dollar change-0.33 Percentage change(-4.87%)
Aftermarket Close
6.17
Aftermarket • 7:30 PM ET Dollar change-0.28 Percentage change(-4.34%)
Index
-
Market Cap
29.53M
Enterprise Value
20.80M
Income
-40.97M
Sales
0.00M
Book/sh
1.20
Cash/sh
1.91
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
40
IPO
May 09, 2019
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
5.37
P/C
3.38
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
2.31
Current Ratio
2.31
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-8.66
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
15.29% -4.25%
Sales past 3/5Y
- -
EPS Y/Y TTM
64.21%
Sales Y/Y TTM
-
EPS Q/Q
59.99%
Sales Q/Q
-
Insider Own
16.30%
Insider Trans
85.81%
Inst Own
61.76%
Inst Trans
18.96%
ROA
-166.16%
ROE
-281.11%
ROIC
-744.50%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
5.41%
SMA50
9.65%
SMA200
-13.11%
Trades
Shs Outstand
4.58M
Shs Float
3.83M
52W High
15.74 -59.02%
52W Low
1.55 316.13%
Volatility
12.38% 14.50%
ATR (14)
0.80
RSI (14)
53.81
Beta
1.12
Rel Volume
0.39
Avg Volume
79.78K
Volume
30,887
Perf Week
0.78%
Perf Month
36.65%
Perf Quarter
9.51%
Perf Half Y
-17.62%
Perf YTD
-54.55%
Perf Year
-29.97%
Perf 3Y
-56.65%
Perf 5Y
-90.73%
Perf 10Y
-
Prev Close
6.78
Price
6.45
Change %
-4.87%
Consensus
Strong Buy
Avg. Price Target
$20.00
Implied Upside
+210.1%
Analysts12incl. previous ratings
Rating Distribution8 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 07, 2025Upgrade
LLadenburg Thalmann
Neutral → Buy$18+179.1%
Nov 04, 2022Downgrade
LLadenburg Thalmann
Buy → Neutral
Mar 01, 2022Initiated
LLadenburg Thalmann
Buy$16+148.1%
Mar 05, 2021Upgrade
TFC logoTTruist
Hold → Buy$19+194.6%
Jan 15, 2021Downgrade
BAC logoBBofA Securities
Neutral → Underperform$10+55.0%
Jul 16, 2020Upgrade
TThe Benchmark Company
Hold → Buy$17+163.6%
Jul 13, 2020Downgrade
SSunTrust
Buy → Hold
Jul 13, 2020Downgrade
RROTH Capital
Buy → Neutral
Jun 01, 2020Downgrade
TThe Benchmark Company
Buy → Hold
Jun 01, 2020Downgrade
BAC logoBBofA/Merrill
Buy → Neutral$62 → $40+520.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADAR1 Capital Management, LLC10% OwnerNov 11 '26Buy5.1012,33362,897750,289Nov 13 04:00 PM
ADAR1 Capital Management, LLC10% OwnerNov 06 '26Buy5.103,66218,676737,956Nov 09 04:19 PM
ADAR1 Capital Management, LLC10% OwnerNov 05 '26Buy5.101,0245,222734,294Nov 09 04:19 PM
ADAR1 Capital Management, LLC10% OwnerOct 23 '26Buy4.835,62627,170728,045Oct 27 07:36 PM
ADAR1 Capital Management, LLC10% OwnerOct 27 '26Buy5.103,55318,104733,270Oct 27 07:36 PM
ADAR1 Capital Management, LLC10% OwnerOct 26 '26Buy5.031,6728,418729,717Oct 27 07:36 PM
Simcere Zaiming, Inc.Former 10% OwnerAug 10 '26Sale6.1630,000184,800308,636Aug 12 11:35 AM
ADAR1 Capital Management, LLC10% OwnerJul 30 '26Buy4.93292,8501,444,746686,116Aug 03 05:53 PM
ADAR1 Capital Management, LLC10% OwnerJul 31 '26Buy4.9436,303179,375722,419Aug 03 05:53 PM
ADAR1 Capital Management, LLC10% OwnerJul 27 '26Buy5.007,79838,985383,456Jul 29 06:18 PM
ADAR1 Capital Management, LLC10% OwnerJul 28 '26Buy4.956,40031,677389,856Jul 29 06:18 PM
ADAR1 Capital Management, LLC10% OwnerJul 29 '26Buy5.003,41017,050393,266Jul 29 06:18 PM
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
Co-FounderMr. Michael S. Richman MSBA
Chief Operating OfficerDr. Timothy Mayer Ph.D.
Ph.D.Dr. Lieping Chen M.D.
Chief Financial OfficerMr. Steven P. Cobourn CPA
Senior VP & General CounselMr. Kevin G. Shaw